MD Anderson Cancer Center Madrid

Hospital


Location: Madrid, Spain (ES) ES

ISNI: 0000000404557543

ROR: https://ror.org/05mq65528

Show on Map:

close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for digestive neuroendocrine carcinoma (2023) Sorbye H, Grande E, Pavel ME, Tesselaar M, Fazio N, Reed NS, Knigge U, et al. Journal article Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial (2022) González-Martín A, Desauw C, Heitz F, Cropet C, Gargiulo P, Berger R, Ochi H, et al. Journal article Streptozotocin, 1982-2022: Forty Years from the FDA's Approval to Treat Pancreatic Neuroendocrine Tumors (2022) Capdevila J, Ducreux M, García Carbonero R, Grande E, Halfdanarson T, Pavel ME, Tafuto S, et al. Journal article, Review article Lu-177-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial (2021) Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, Mittra E, et al. Journal article The Phase 3 NETTER-1 Study of [Lu-177]Lu-DOTA-TATE in Patients with Midgut Neuroendocrine Tumours: Final Overall Survival and Long-Term Renal Safety (2021) Kunz P, Caplin ME, Ruszniewski PB, Bodei L, Hendifar A, Mittra E, Wolin EM, et al. Conference contribution ENETS consensus guidelines for synoptic reporting of radiology studies (2021) Dromain C, Vullierme MP, Hicks RJ, Prasad V, O'Toole D, De Herder WW, Pavel ME, et al. Journal article The phase III NETTER-1 study of 177Lu-DOTATATE in patients with midgut neuroendocrine tumours: Further survival analyses (2021) Ruszniewski PB, Caplin ME, Kunz PL, Bodei L, Hendifar AE, Mittra E, Wolin EM, et al. Conference contribution A phase II randomized study of neoadjuvant letrozole plus alpelisib for hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (NeO-ORB) (2019) Mayer IA, Prat A, Egle D, Blau S, Alejandro Perez Fidalgo J, Gnant M, Fasching P, et al. Journal article Changes in Weight Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome (2018) Weickert MO, Kaltsas G, Hoersch D, Lapuerta P, Pavel ME, Valle JW, Caplin ME, et al. Journal article